Compare AstraZeneca plc (AZN) vs Rockwell Automation (ROK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Rockwell Automation — how do they compare? AstraZeneca plc trades at $167.1 (market cap $253.13B), while Rockwell Automation trades at $472.3 (market cap $52.27B). The key difference: AstraZeneca plc is far larger — about 4.8× Rockwell Automation's market cap, and AstraZeneca plc pays the higher dividend (1.92%). Which is the better fit depends on your goals.
| AZN | ROK | |
|---|---|---|
Market Cap | $253.13B | $52.27B |
Sector | Health | Industrials |
52-Week High | $209.48 | $495.08 |
52-Week Low | $137.44 | $328.67 |
Enterprise Value | $279.37B | $55.90B |
Dividend Yield | 1.92% | 1.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
Rockwell Automation (ROK) trades at $460.45, down 2.47% today, with a neutral technical signal and bullish moving averages. The company shows strong profitability with 48.92% gross margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights leadership in industrial automation and AI integration, including new FactoryTalk software launches and WEF recognition for its Singapore facility.
ROK presents a mixed outlook with solid fundamentals but premium valuation (P/E 47.81). Analyst consensus is cautious with 64% hold ratings, though price targets suggest modest upside to $471.71. Key risks include execution challenges in scaling MES integration and industrial sector volatility. The stock offers growth exposure to industrial automation trends with dividend income support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Rockwell Automation
Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →
